Back to search

University of British Columbia

Exploring the feasibility of in situ gene editing on skin for the treatment of genodermatoses

Abstract

dc:description

Genodermatoses are genetic skin disorders with currently no curative treatment. The fast-paced advancement of gene therapy tools offers a solution for the treatment and cure of genodermatoses. Autosomal Recessive Congenital Ichthyosis (ARCI) is a genetic skin disorder that greatly affects the life-quality of the patient. Here, we hypothesized that the gene editing tool CRISPR-Cas9 can be delivered by lipid nanoparticles into primary human keratinocytes and skin tissue, and genetically edit the epidermis cells. Initially, we screened different formulations of LNPs for physical (size, PDI, zeta potential) and biological (cell viability, gene editing efficacy) characteristics. The first trials suggested DOPE LNPs shows less cytotoxicity (>60%) and higher gene editing efficacy for RNP (14%) and mRNA (15%) approaches. After selecting one formulation in a 2D in vivo approach, we moved to 3D systems: reconstructed skin models and ex vivo excised skin. Also, to improve the penetration of the LNPs into the epidermis, we used 400μm solid microneedles that can create micro-sized openings in the skin and facilitate the permeation of particles. Skin models showed gene editing efficacy of 8-15% for both RNP- and mRNA-loaded LNPs. Similarly, excised human skin indicates gene editing of 9% for RNPloaded and 7% for mRNA-loaded LNPs. To further explore the capacity of CRISPR-loaded LNPs, we tested LNP formulations varying in ionizable lipids. LNPs A-J formulated with different ionizable lipids indicates a significant increase in gene editing efficacy, especially for LNP E (37%) and LNP H (72%), but impaired cell viability (<50%). We also tested the addition of saponins as endosomal escape enhancer, but there were no significant changes in gene editing efficacy. Finally, we tested the use of modified LNPs by adding the cell penetrating peptide Tat. The Tat-LNPs showed an increase in GFP expression when compared to DOPE LNPs, but a lower cell viability. In conclusion, results suggest LNPs loaded with CRISPR-Cas9 components can be delivered in primary human keratinocytes and skin tissue and induce in situ genome editing.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Pharmaceutical Sciences
Grantor dc:publisher
University of British Columbia
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • de Andrade Bolsoni, Juliana
Contributors dc:contributor
  • Li, Shyh-Dar
  • Hedtrich, Sarah

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/84132

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

de Andrade Bolsoni, Juliana. Exploring the feasibility of in situ gene editing on skin for the treatment of genodermatoses. master's thesis, University of British Columbia, 2023. http://hdl.handle.net/2429/84132